

**Consolidated Financial Statements for the First Quarter Ended June 30, 2017  
FY2017 (April 1, 2017 - March 31, 2018)**

July 27, 2017

Company name: Takara Bio Inc.  
 Stock exchange listings: Tokyo Stock Exchange (1st section)  
 Code number: 4974  
 URL: <http://www.takara-bio.co.jp>  
 Company representative: Koichi Nakao, President  
 Contact: Shuichiro Matsuzaki, Executive Vice President  
 Tel. (077) 565-6970

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.  
 2. Amounts are rounded down to the nearest million yen.

**1. Results for the three months ended June 30, 2017 (April 1, 2017 – March 31, 2018)**

**(1) Operating results**

(Percentages indicate changes from the same period of the previous fiscal year.)

	Three months ended June 30, 2017		Three months ended June 30, 2016	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	6,355	0.8	6,306	9.5
Operating income	262	(59.2)	643	476.3
Ordinary income	287	(56.0)	653	200.2
Net income (loss) attributable to owners of the parent	22	(92.0)	285	-
Net income per share (in yen)	0.19		2.37	
Fully diluted net income per share (in yen)	-		-	
Note: Comprehensive income	(751)	-	(807)	-

**(2) Financial position**

	As of June 30, 2017	As of March 31, 2017
	(Millions of yen)	(Millions of yen)
Total assets	65,814	67,143
Net assets	58,752	59,985
Equity ratio (%)	89.1	89.2
Net assets per share (in yen)	487.06	497.32
(Reference) Equity	58,649	59,884

**2. Dividends**

Annual dividends per share in yen

	Year ended March 31, 2017	Year ended March 31, 2018	Year ending March 31, 2018(Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	4.00		4.00
Annual	4.00		4.00

**3. Forecast for the year ending March 31, 2018 (April 1, 2017 – March 31, 2018)**

(Percentages indicated changes from the same period of the previous fiscal year.)

	Six months ending September 30, 2017		Year ending March 31, 2018	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	14,049	6.4	33,200	13.0
Operating income	487	(64.6)	3,300	3.0
Ordinary income	523	(63.7)	3,600	0.6
Net income attributable to owners of the parent	18	(97.2)	1,850	36.7
Net income attributable to owners of the parent per share (in yen)	0.16		15.36	

#### 4. Others

- (1) Material changes in subsidiaries during this period  
(Changes in scope of consolidations resulting from change in subsidiaries) : Yes  
Newly include : 2 (Name) WaferGen Bio-systems, Inc., Rubicon Genomics, Inc.  
Excluded : 1 (Name) Rubicon Genomics, Inc.
- (2) Applying of specific accounting of the consolidated quarterly financial statements : No
- (3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
- 1) Changes based on revisions of accounting standard: No
  - 2) Changes other than ones based on revisions of accounting standard: No
  - 3) Changes in accounting estimates: No
  - 4) Restatement: No
- (4) Number of outstanding shares (common stock)
- 1) Number of outstanding shares at year end (Treasury stocks are included)

As of June 30, 2017:	120,415,600
As of March 31, 2017:	120,415,600
  - 2) Number of treasury stocks at year end

As of June 30, 2017:	-
As of March 31, 2017:	-
  - 3) Average number of outstanding shares

As of June 30, 2017:	120,415,600
As of March 31, 2017:	120,415,600